RxDoctor Payments Data

Amir Kichloo, MD

Hospitalist · Bismarck, NDNPI 1194978734

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $235 and has fallen 51.6% since, to $114 in 2025.

$544in general payments, 2019–2025

Across 28 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$110
  • Pfizer$107
  • Lexicon Pharmaceuticals, Inc.$62
  • Gilead$50
  • Novo Nordisk$38
  • Johnson & Johnson$36
  • plus $141 from 6 others

What the payments were for

  • Food & beverage$544100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$544 in reported general payments places this provider in the 85th percentile of 114 hospitalist providers in North Dakota.

See all hospitalist providers in North Dakota

Medicare billing

Part B allowed, 2024
$66,020
Medicare patients
279
Services billed
849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$29,378
EliquisApixaban24$11,446
JanuviaSitagliptin Phosphate15$9,068
Spiriva RespimatTiotropium Bromide16$8,253
Bumetanide13$423
Metoprolol Succinate29$406
Potassium Chloride23$367
ClopidogrelClopidogrel Bisulfate28$317
Pantoprazole Sodium18$184
Omeprazole15$178
Gabapentin11$170
Losartan Potassium13$139
Amlodipine Besylate17$123
Furosemide16$121
Carvedilol15$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$20$37,63158 claims
PfizerEliquis$107$11,44624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 114 hospitalist providers in North Dakota.

Other hospitalist in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →